Overall survival of patients with CLL treated with ibrutinib in the first line compared to second-line ibrutinib after chemotherapy/chemoimmunotherapy-Reference-Cited by-同舟云学术

Overall survival of patients with CLL treated with ibrutinib in the first line compared to second-line ibrutinib after chemotherapy/chemoimmunotherapy

Published:2024-07 Issue:8 Volume:40 Page:1369-1378
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Robak Tadeusz¹,Doubek Michael²,Ferrant Emmanuelle³,Diels Joris⁴,Andersone Liva⁵,Wilbertz Sabine⁶,Healy Nollaig C.⁷,Neumayr Lynne⁸,van Sanden Suzy⁴

Affiliation:

1. Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland

2. Internal Medicine – Hematology and Oncology Department, University Hospital Brno, Brno, Czech Republic

3. Department of Hematology, Hôpital Lyon-Sud, Lyon, France

4. Janssen Pharmaceutica NV, Beerse, Belgium

5. UAB “JOHNSON & JOHNSON” filiale Latvija, Riga, Latvia

6. Janssen-Cilag GmbH, Neuss, Germany

7. Janssen Sciences Ireland UC, Cork, Ireland

8. Pharmacyclics, an AbbVie Company, Sunnyvale, California, USA

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2024.2368175

Reference32 articles.

1. IMBRUVICA® (ibrutinib) [SmPC]. Janssen-Cilag International NV. Beerse, Belgium; 2023.

2. IMBRUVICA® (ibrutinib) [prescribing information]. Pharmacyclics LLC. Sunnyvale, CA: Janssen Biotech, Inc., Horsham, PA; 2023.

3. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

4. Špaček M, Šimkovič M, Pospíšilová Š, et al. 7. Chronická lymfocytární leukemie [Chronic lymphocytic leukemia]. In: Doubek M, Mayer J, editors. Léčebné postupy v hematologii 2023 [Treatments in hematology 2023]. Brno, Czech Republic: Česká hematologická společnost ČLS JEP; 2023.

5. Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results